Conversely, the Swiss registry suggests that early anti-TNF-α treatment (<24 months after diagnosis) significantly reduces the risks of low BMD and osteoporosis after a 10-year follow-up (11.4% vs. 28.2%, p < 0.001) [23]. The gene discussed is TNF; the disease is osteoporosis.